Primary Care Clinics in Carolina Shores, NC Accepting Medicare
1 Primary Care Clinics found. Showing 1 - 1
 Novant Health Family & Internal Medicine South Brunswick Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 75 Emerson Bay Street Sw, Suite 102, Carolina Shores, NC 28467 Phone: 910-579-8363 Fax: 910-579-8306 |
News Archive
BioSante publishes oral insulin study
BioSante Pharmaceuticals, Inc. has announced the publication of positive results of a preclinical study of its proprietary calcium phosphate nanoparticle (CAP) delivery system for the oral delivery of insulin in the June 11 issue of the peer-reviewed International Journal of Pharmaceutics.
CFDA accepts WuXi MedImmune's novel anti-IL6 monoclonal antibody IND application for review
WuXi PharmaTech (Cayman) Inc., a leading open-access R&D capability and technology platform company serving the global pharmaceutical, biotechnology, and medical device industries, announced today that an Investigational New Drug (IND) application for WuXi MedImmune's novel anti-IL6 monoclonal antibody for rheumatoid arthritis has been accepted for review by the China Food and Drug Administration.
New Johns Hopkins Lyme Disease Clinical Research Center launched
Fundamental research into the causes and cures of post-treatment Lyme disease syndrome now has its first home base at a major U.S. medical research center with the launch of the Johns Hopkins Lyme Disease Clinical Research Center. Inaugurated on May 12, 2015, with a major gift from the Lyme Disease Research Foundation, the center plans an ambitious research program targeting this increasingly common disease, which costs the U.S. economy up to $1.3 billion per year in treatment costs alone.
Caraco Pharmaceutical Labs announces FDA approval to market generic Tenormin
Caraco Pharmaceutical Laboratories has announced that the US Food and Drug Administration (FDA) has granted final approval for the Company's Abbreviated New Drug Application (ANDA) for Atenolol Tablets USP (atenolol).
DURATION-4 study tests superiority of BYDUREON as compared to other type 2 diabetes medications
Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced results from DURATION-4, the fourth in a series of studies designed to test the superiority of BYDUREON (exenatide extended-release for injectable suspension), an investigational type 2 diabetes therapy, as compared to other type 2 diabetes medications.
› Verified 8 days ago